[Effect of repeated injections of sandostatine, with increasing doses, in the treatment of 40 acromegalics. French Group for the study of Sandostatine in XXXX ].

@entity1 @entity2012 @entity10 @entity5
SMS 201-995 was administered to 40 acromegalic @entity1 , in a multicentric study. Some of the results have been analyzed from 37 @entity1 who remained under a long term treatment. Clinical improvement was noted in most @entity1 , especially as concerns soft tissue swelling, sweating, @entity10 . Digestive adverse effects were noted, leading to the drop-out from the protocol (in 4 @entity1 ) or in most @entity1 to a slight discomfort related to increasing doses. There was an effect for all the doses used (300, 600, 900, 1500 micrograms in 3 subcutaneous injections per day), compared with pretreatment values, if we consider the mean GH value of each cycle obtained under the different dosages. The highest dose was most effective than the lowest in some cases. However in most @entity1 the 300 micrograms dose was efficient. We could not obtain normalization of GH secretion. However 22/37 @entity1 could reach a good score as concerns the number of GH values less than 5 micrograms/l, during circadian evaluations. In 5/37 patients, the antisecretory effect was insufficient (mean GH above 50% of the pretreatment level). Reduction in @entity5 volume was highly significant (more than 50%) in 2/11 @entity1 . In conclusion, this study shows the efficacy of SMS 201-995 in improving clinical signs and symptoms of @entity2012 , and GH hypersecretion in approximately 80% of the @entity1 . General and metabolic tolerance are rather good. Some points concerning tolerance remain to be investigated.
